Surgical, Oncological, and Functional Outcomes of Transoral Robotic Supraglottic Laryngectomy. (23rd July 2020)

• Record Type: Journal Article
• Authors: Hans, Stéphane; Chekkoury‐Idrissi, Younès; Circiu, Marta P.; Distinguin, Léa; Crevier‐Buchman, Lise; Lechien, Jérôme R.
• Is Part Of: Laryngoscope. Volume 131:Number 5(2021)
• Page Start: 1060
• Page End: 1065
• Publication Date: 2020-07-23
• Subjects: Laryngectomy -- partial -- supraglottic -- cancer -- larynx -- laryngeal -- robot -- robotic -- transoral -- outcomes; Otolaryngology -- Periodicals; 617.51005
• DOI: 10.1002/lary.28926
• Languages: English
• ISSNs: 0023-852X

Abstract

Abstract : Objectives/Hypothesis: To investigate the surgical, oncological, and functional outcomes of transoral robotic surgery (TORS) for the treatment of supraglottic squamous cell carcinoma. Study Design: Retrospective chart review. Methods: The charts of patients treated by TORS supraglottic laryngectomy (SGL) in an academic medical center were reviewed. The following outcomes were studied according to the tumor location: average robotic setup and operative times, mean estimated blood loss, postoperative complications, need of tracheotomy, refeeding characteristics, mean hospital stay, need of neck dissection and adjuvant therapy, 5‐year local and regional controls, overall survival (OS), and disease‐free survival (DFS). Results: Seventy‐five patients underwent TORS SGL. Tumors were classified as cT1 (32%), cT2 (52%), and cT3 (16%). Average robotic setup and operative times and the mean estimated blood loss were 15 minutes, 55 minutes, and 20 mL, respectively. The mean follow‐up period ranged from 2 to 5 years. The 5‐year OS and DFS were 80.2% and 94.3%, respectively. Overall, 34.6% of patients received adjuvant radiotherapy. The majority of patients (92%) restarted an oral diet within 24 to 48 hours postsurgery. Transient tracheotomy was performed in 8% of patients. Postoperative hemorrhages occurred in 12 patients (16.0%), lengthening the hospital stay (mean = 6.8 days). There were no outcome differences regarding the tumor location. Conclusions: TORS is an effective and safe therapeutic approach for early‐ and intermediate‐stages cancers. Oncological outcomes may be quite similar to other surgical approaches, including transoral laser and open surgeries. Future randomized controlled studies are needed for comparing TORS SGL with other surgical procedures. Level of Evidence: 4 Laryngoscope, 131:1060–1065, 2021